文献速递淋巴瘤

基于MALT-IPI与血清β2微球蛋白的结外边缘区淋巴瘤预后指数

A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
PubMed 文献 · Br J Haematol · 2020-11-20

研究在571例MALT淋巴瘤患者中分析血清β2微球蛋白与MALT-IPI的预后价值,并在216例独立队列中验证新指数MALT-IPI-B。高β2微球蛋白者PFS和OS显著更差,且为独立不良因素;MALT-IPI-B可将患者分为PFS和OS不同的亚组,并识别MALT-IPI中危组中预后差者。

要点

  • 高血清β2微球蛋白水平与MALT淋巴瘤患者PFS和OS显著更差相关。
  • β2微球蛋白可进一步区分MALT-IPI中危组患者的PFS和OS。
  • 新指数MALT-IPI-B在训练和验证队列中均可分层PFS和OS。

核心结论

  • 基于β2微球蛋白的MALT-IPI-B预后指数可识别可能需要全身治疗的高危MALT淋巴瘤患者。

研究设计与样本

  • 回顾性分析571例MALT淋巴瘤患者的生存结局,并在216例独立队列中验证新预后指数。

主要发现

  • 高β2微球蛋白水平患者PFS和OS显著更差。
  • 高β2微球蛋白水平与不良PFS和OS独立相关。
  • β2微球蛋白水平进一步分层MALT-IPI中危组的PFS和OS。
  • MALT-IPI-B在训练和验证队列中均可将患者分为PFS和OS不同的亚组。
  • MALT-IPI-B可识别被MALT-IPI归为中危但生存结局差的患者。

关键数值与推荐

  • MALT-IPI-B基于MALT-IPI和血清β2微球蛋白水平构建。

临床怎么用

  • 对MALT淋巴瘤患者可结合MALT-IPI与血清β2微球蛋白水平评估预后。
  • MALT-IPI-B有助于识别MALT-IPI中危组中可能需要全身治疗的高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The mucosa-associated lymphoid tissue (MALT) International Prognostic Index (IPI) was recently proposed as a prognostic index for patients with MALT lymphoma. We aimed to investigate the prognostic value of the serum β2-microglobulin level in the context of MALT-IPI, and we proposed a new prognostic index. Survival outcomes were analysed with regard to β2-microglobulin level, MALT-IPI, and the new prognostic index in MALT lymphoma patients (n = 571). The validity of the new prognostic index was assessed using an independent cohort (n = 216). Patients with high β2-microglobulin levels had significantly worse progression-free survival (PFS) and overall survival (OS) outcomes. A high β2-microglobulin level was independently associated with poor PFS and OS. β2-microglobulin levels further stratified patients in the MALT-IPI intermediate-risk group in terms of PFS and OS. A new prognostic index based on the MALT-IPI and the β2-microglobulin level, MALT-IPI-B, was proposed. The MALT-IPI-B was able to stratify patients into subgroups having distinct PFS and OS outcomes in both the training and validation cohorts. MALT-IPI-B enabled the identification of patients with poor survival outcomes who were classified into the intermediate-risk group by the MALT-IPI. In conclusion, this new β2-microglobulin-based prognostic index may have the specific advantage of identifying high-risk patients who may require systemic treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kim HD, Cho H, Jeong H, et al. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels. Br J Haematol. 2020. PMID: 33216979. doi:10.1111/bjh.17222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。